Previous studies showed that lenalidomide activated NK cells and enhanced NK cell function in MM patients, and its effects on NK cells were dependent on CD4+T cells and IL-2 secretion [24, 25]. The gene discussed is IL2; the disease is Miyoshi myopathy.